ProAssurance (PRA) Proxy Filing summary

Executive summary

• A special meeting is scheduled for June 24, 2025, for shareholders to vote on a proposed merger with The Doctors Company, making the company a wholly owned subsidiary and providing $25.00 per share in cash, a 58.8% premium over the pre-announcement price.

• The board unanimously recommends voting in favor of the merger, the executive compensation proposal, and the adjournment proposal if needed.

• The merger is subject to regulatory approvals, shareholder approval, and other customary closing conditions, with completion expected in the first half of 2026.

Voting matters and shareholder proposals

• Shareholders will vote on: (1) the merger agreement, (2) a non-binding advisory vote on executive compensation related to the merger, and (3) a proposal to adjourn the meeting if more time is needed to solicit votes.

• Approval of the merger requires a majority of outstanding shares; the executive compensation and adjournment proposals require a majority of shares present or represented by proxy.

• Dissenting shareholders may seek appraisal rights under Delaware law.

Board of directors and corporate governance

• The board formed a transaction committee to oversee negotiations and strategic alternatives.

• The board conducted a strategic review, contacted six potential acquirers, and determined the merger consideration was the highest value reasonably obtainable.

• The board considered the interests of directors and officers, including potential conflicts, and disclosed these to shareholders.